Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results matching your filters

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular DegenerationRecruiting
NCT07614776Phase 3Updated Sep 8, 2026
Sponsor: Amgen
Neovascular Age-related Macular Degeneration · nAMD
United States, Latvia, Poland, Slovakia
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative ColitisRecruiting
NCT07158242Phase 3Updated Sep 8, 2026
Sponsor: Hoffmann-La Roche
Moderately to Severely Active Ulcerative Colitis
United States, Australia, Brazil, Canada, China +4 more
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)Recruiting
NCT05125302Phase 3Updated Sep 8, 2026
Sponsor: AbbVie
Migraine
United States, Puerto Rico
Assess the Efficacy of OM-89 vs Placebo in Reducing Antibiotic Consumption Associated With the Treatment of Urinary Tract Infections in Patients With Neurogenic BladderRecruiting
NCT06588010Phase 3Updated Sep 8, 2026
Sponsor: Centre Hospitalier Universitaire Dijon
Neurogenic Bladder
France
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruiting
NCT06890598Phase 3Updated Sep 8, 2026
Sponsor: Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
United States, Australia, Austria, Belgium, Brazil +24 more
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue DiseaseRecruiting
NCT06572384Phase 3Updated Sep 8, 2026
Sponsor: GlaxoSmithKline
Lung Diseases, Interstitial
United States, Argentina, Australia, Belgium, Brazil +13 more
Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)Recruiting
NCT07016321Phase 2, Phase 3Updated Sep 8, 2026
Sponsor: Johns Hopkins University
Dengue
United States, Nepal
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)Recruiting
NCT07174336Phase 3Updated Sep 8, 2026
Sponsor: Eli Lilly and Company
Breast Neoplasms · Neoplasm Metastasis
United States, Argentina, Australia, Belgium, Brazil +14 more
Midodrine in Heart Failure With Reduced Ejection Fraction With HypotensionRecruiting
NCT06405555Phase 2, Phase 3Updated Sep 8, 2026
Sponsor: Ottawa Heart Institute Research Corporation
Heart Failure With Reduced Ejection Fraction · Hypotension · LV Dysfunction
Canada
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)Recruiting
NCT07361497Phase 3Updated Sep 8, 2026
Sponsor: Bristol-Myers Squibb
Non-small Cell Lung Cancer (NSCLC)
United States, Argentina, Australia, Austria, Belgium +27 more
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)Recruiting
NCT07361510Phase 3Updated Sep 8, 2026
Sponsor: Bristol-Myers Squibb
Non-Small Cell Lung Cancer (NSCLC)
United States, Argentina, Australia, Austria, Belgium +31 more
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - WomenRecruiting
NCT06399692Phase 3Updated Sep 8, 2026
Sponsor: Weill Medical College of Cornell University
Coronary Artery Disease
United States
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)Recruiting
NCT07241390Phase 3Updated Sep 8, 2026
Sponsor: Eli Lilly and Company
Atherosclerosis Cardiovascular Disease · Chronic Kidney Disease
Argentina, Australia, Austria, Belgium, Brazil +33 more
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseaseRecruiting
NCT07223593Phase 3Updated Sep 8, 2026
Sponsor: Eli Lilly and Company
Peripheral Arterial Disease
United States, Argentina, Australia, Brazil, Canada +12 more
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)Recruiting
NCT07340827Phase 3Updated Sep 8, 2026
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Infertility
Japan
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Recruiting
NCT07165028Phase 3Updated Sep 8, 2026
Sponsor: Eli Lilly and Company
Metabolic Dysfunction-Associated Steatotic Liver Disease
United States, Argentina, Australia, Austria, Belgium +29 more
A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular DiseaseRecruiting
NCT07551492Phase 3Updated Sep 8, 2026
Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Atherosclerotic Cardiovascular Disease
China
Semaglutide for Smoking Cessation in Patients With DiabetesRecruiting
NCT07059377Phase 3Updated Sep 8, 2026
Sponsor: Ottawa Heart Institute Research Corporation
Diabetes Mellitus, Type 2 · Nicotine Addiction · Tobacco Dependence
Canada
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.Recruiting
NCT07629440Phase 3Updated Sep 8, 2026
Sponsor: Pfizer
Pneumococcal Disease
United States, Japan, Puerto Rico
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesRecruiting
NCT07282600Phase 3Updated Sep 8, 2026
Sponsor: Eli Lilly and Company
Overweight · Obesity
United States, Argentina, China, Czechia, Germany +9 more
A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)Recruiting
NCT07807865Phase 3Updated Sep 8, 2026
Sponsor: Intra-Cellular Therapies, Inc.
Generalized Anxiety Disorder
United States
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 SkippingRecruiting
NCT07587242Phase 3Updated Sep 8, 2026
Sponsor: Avidity Biosciences, Inc.
Muscular Dystrophies · Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy) · Muscular Disorders, Atrophic · Muscular Disease
Belgium, France, Germany, Italy, Spain +1 more
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)Recruiting
NCT06338995Phase 3Updated Sep 8, 2026
Sponsor: Eli Lilly and Company
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
United States, Argentina, Belgium, Bulgaria, Canada +15 more
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)Recruiting
NCT07220083Phase 3Updated Sep 8, 2026
Sponsor: Boehringer Ingelheim
Focal Segmental Glomerulosclerosis
United States, Argentina, Australia, Belgium, Brazil +35 more
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)Recruiting
NCT06345729Phase 3Updated Sep 8, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
United States, Argentina, Australia, Austria, Brazil +22 more

Previous page Next page